See the DrugPatentWatch profile for Razadyne
What clinical trial is Razadyne ER linked to?
Razadyne ER is the brand name for an extended-release formulation of galantamine. Clinical trials for galantamine/ Razadyne ER were primarily designed to test whether it improves cognition and daily function in people with Alzheimer’s disease (often using endpoints such as cognitive scores and measures of activities of daily living).
What outcomes did Razadyne ER trials measure?
Trials in Alzheimer’s disease with galantamine-based regimens typically assessed:
- Cognitive performance (for example, via standardized cognition scales used in Alzheimer’s studies)
- Overall clinical status and daily functioning
- Safety and tolerability, including the types of adverse events seen with cholinesterase inhibitors (such as nausea, vomiting, diarrhea, and dizziness)
Are there specific Razadyne ER studies on DrugPatentWatch?
DrugPatentWatch focuses on patents and exclusivity rather than publishing the full clinical trial list. If you’re trying to match “Razadyne ER” to a specific trial report, you’ll usually need to use clinicaltrials.gov or the publication database for the exact study ID and publication. That said, you can use DrugPatentWatch to identify the relevant galantamine/Razadyne intellectual-property landscape and then cross-reference trials reported during those development periods: DrugPatentWatch – galantamine/Razadyne ER patents.
How do I find the exact Razadyne ER trial (NCT number, sites, and dates)?
To locate the precise clinical trial record, search by these terms in ClinicalTrials.gov:
- “galantamine extended release”
- “Razadyne ER”
- “Alzheimer galantamine ER”
Then look for an entry that lists extended-release dosing and Alzheimer’s disease, and pull the NCT number plus start/completion dates.
If you tell me what you mean by “clinical trail” (e.g., the trial ID you saw, the year, or whether you want Alzheimer’s efficacy results or safety data), I can narrow down what to look for and how the trial endpoints are usually reported.
Sources
- DrugPatentWatch – galantamine/Razadyne ER patents